Back to Search
Start Over
Thrombin as target for prevention of recurrent events after acute coronary syndromes.
- Source :
-
Thrombosis Research . Mar2024, Vol. 235, p116-121. 6p. - Publication Year :
- 2024
-
Abstract
- The mechanism underlying thrombus formation in acute coronary syndrome (ACS) involves both platelets and thrombin. While both pathways are targeted in acute care, platelet inhibition has been predominantly administered in the chronic phase, yet thrombin plays a key role in platelet activation and fibrin formation. Among ACS patients, there is also a persistent chronic increase in thrombin generation, which is associated with a higher rate of adverse events. In the setting of post-ACS care with rivaroxaban or vorapaxar, targeting thrombin has been associated with decreased thrombin generation and reduced cardiovascular events, but has been associated with increased bleeding risk. We explored the evidence supporting thrombin generation in the pathophysiology of recurrent events post-ACS and the role of thrombin as a viable therapeutic target. One specific target is factor XI inhibition, which is involved in thrombin generation, but may also allow for the preservation of normal hemostasis. • Thrombin generation remains elevated post-ACS • Elevated thrombin levels are associated with higher event rates • Strategies targeting thrombin improve outcomes, but increase bleeding • Factor XI inhibition may reduce ischemic events without major bleeding [ABSTRACT FROM AUTHOR]
- Subjects :
- *ACUTE coronary syndrome
*THROMBIN
*BLOOD platelet activation
Subjects
Details
- Language :
- English
- ISSN :
- 00493848
- Volume :
- 235
- Database :
- Academic Search Index
- Journal :
- Thrombosis Research
- Publication Type :
- Academic Journal
- Accession number :
- 175698407
- Full Text :
- https://doi.org/10.1016/j.thromres.2024.02.003